Parts of this article (those related to status and trials) need to be updated.(December 2021) |
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | mRNA |
Clinical data | |
Other names | CVnCoV CV07050101 |
Routes of administration | Intramuscular |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
DrugBank | |
UNII |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
The CureVac COVID-19 vaccine (abbreviated CVnCoV) was a COVID-19 vaccine candidate developed by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations (CEPI).[3] The vaccine showed inadequate results in its Phase III trials with only 47% efficacy.[4] In October 2021 CureVac abandoned further development and production plans for CVnCoV and refocused efforts on a cooperation with GlaxoSmithKline.[5]